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ORIGINAL PAPER
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Abstract
Autosomal Dominant Polycystic Kidney Disease is characterised by the development of fluid-filled cysts in the
kidneys which lead to end-stage renal disease (ESRD). In the majority of cases, the disease is caused by a mutation
in the Pkd1 gene. In a previous study, we demonstrated that renal injury can accelerate cyst formation in Pkd1
knock-out (KO) mice. In that study, we found that after injury four-jointed (Fjx1), an upstream regulator of planar
cell polarity and the Hippo pathway, was aberrantly expressed in Pkd1 KO mice compared to WT. Therefore, we
hypothesised a role for Fjx1 in injury/repair and cyst formation. We generated single and double deletion mice
for Pkd1 and Fjx1, and we induced toxic renal injury using the nephrotoxic compound 1,2-dichlorovinyl-cysteine.
We confirmed that nephrotoxic injury can accelerate cyst formation in Pkd1 mutant mice. This caused Pkd1 KO
mice to reach ESRD significantly faster; unexpectedly, double KO mice survived significantly longer. Cyst formation
was comparable in both models, but we found significantly less fibrosis and macrophage infiltration in double KO
mice. Taken together, these data suggest that Fjx1 disruption protects the cystic kidneys against kidney failure
by reducing inflammation and fibrosis. Moreover, we describe, for the first time, an interesting (yet unidentified)
mechanism that partially discriminates cyst growth from fibrogenesis.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Autosomal Dominant Polycystic Kidney Disease
(ADPKD) is a genetic disease caused in the majority
of the cases by a mutation in the PKD1 gene, which
encodes polycystin 1, and in the remaining cases by
a mutation in the PKD2 gene, encoding polycystin 2
[1]. The hallmark of this disease is the formation of
fluid-filled cysts in the kidneys, which grow slowly and
progressively disrupt the renal parenchyma, ultimately
leading to kidney failure [1,2]. The exact mechanisms
behind cyst formation are still elusive, and effective
therapies are still missing, although the Vasopressin
V2R antagonist tolvaptan has become recently available
for selected patients [3–5].
Recently, our group showed that a substantial proportion of genes typically deregulated in ADPKD also play
roles in injury-repair mechanisms [6]. Indeed, since less

than a decade ago, injury has emerged as an important
player in cyst formation and progression, and now it is
considered a ‘modifier’ of ADPKD [7]. Several other
groups, and we, have described that both nephrotoxic
[8] and ischaemic injury, as well as unilateral nephrectomy [9–12], were able to speed up cyst formation and
progression, reinforcing the link between ADPKD progression and injury. In particular, we identified one gene,
four-jointed box kinase 1 (Fjx1), as an interesting player
in these processes. In our study, Fjx1 showed aberrant expression during both the injury-repair phase and
cyst progression in Pkd1 KO mice compared with WT
mice [8]. Moreover, Fjx1 is implicated with two important pathways normally aberrant in ADPKD: planar cell
polarity (PCP) and the Hippo pathway.
Fjx1 is the mammalian homolog of the Drosophila
protein Fj, discovered for its pivotal role in the correct
development of leg joints, wings and eyes [9,10]. Fj
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regulates the interaction of Fat (Ft) with Dachsous (Ds),
which controls PCP signalling, most likely in parallel
with the Frizzled signals [10–12]. Fj mutant Drosophila
models have a clear alteration of PCP, whereas Fjx1
KO mice do not show any morphological defects in the
kidneys or other organs [13,14]. However, deleting the
target of Fjx1, Fat4, leads to loss of PCP in the inner
ear, cochlea and the neural tube, and mild cyst formation
in mouse kidney. Loss of both, Fat4 and Fjx1, slightly
aggravates the phenotype, suggesting that Fjx1 may also
act via Fat4-independent pathways. Yet, the effect of
Fjx1 in a Pkd1 mutant context is to date unknown [14].
In Drosophila, Fj is also an upstream regulator of
the Hippo pathway, through its downstream target
Ft. The Hippo pathway regulates proliferation and
tissue size through the activity of the final effector
and transcriptional co-activator Yorki (Yki) [15,16]. In
mammals, there are two Yki orthologs: Yes-associated
protein 1 (Yap1) and transcriptional coactivator with
PDZ-binding motif (Wwtr1 or Taz). When the Hippo
pathway is active, Yap1 and Taz are phosphorylated
and retained in the cytoplasm, preventing their nuclear
translocation and transcriptional activity. In ADPKD,
Yap and Taz activity is upregulated in the cyst lining
epithelium as indicated by their nuclear localisation,
suggesting a role for this pathway in cyst progression
[17]. In mammals, regulation of the Hippo pathway by
Fat4 has recently been shown in the prenatal heart [18];
however, whether this regulatory mechanism also takes
place in the kidneys is not clear [14,19].
This study aimed to investigate the role of Fjx1 during
ADPKD progression, particularly after kidney injury
and the involvement of the PCP and Hippo pathways. We
found that mice that are double KO for Fjx1 and Pkd1
display cyst formation comparable to that of single Pkd1
KO mice but survive longer. This effect was probably
not due to differences in PCP and the Hippo pathway,
which were unaffected by Fjx1 deletion, but rather due
to reduced fibrosis and macrophage infiltration in the
double KO mice. We also found a reduction of fibrosis
which was independent of cyst formation. Indeed, in
our study, reduced fibrogenesis was caused directly by
Fjx1 deletion and was not an indirect consequence of
the improved cystic phenotype.

Methods
Animal models
All the animal experiments were evaluated and approved
by the local animal experimental committee of the
Leiden University Medical Centre and the Commission Biotechnology in Animals of the Dutch Ministry
of Agriculture. The kidney-specific tamoxifen-inducible
Pkd1-deletion mouse model (Pkd1-cKO) and the
Fjx1−/− (Fjx1 KO) has been described previously
[13,20]. By cross-breeding Pkd1-cKO with the Fjx1
KO mice, we generated the Fjx1−/− /Pkd1-cKO double
KO mouse model (double KO). Inactivation of the Pkd1
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gene was achieved by oral administration of tamoxifen
(Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) in
adult mice (13–14 weeks old). Renal injury was induced
a week after gene disruption by a single i.p. injection
of S-(1,2-dichlorovinyl)-L-cysteine (DCVC) or vehicle. Injury was evaluated by measurement of blood
urea nitrogen (BUN) level after 40 h, as described [8].
More details are provided in supplementary material,
Supplementary materials and methods.

Immunohistochemistry
Formalin-fixed paraffin-embedded kidneys were
sectioned at 4 μm thickness. Sections were stained
with PAS to determine the cystic index (CI) and with
picro-sirius red (PSR) to determine fibrotic index.
Kidney sections were also stained for αSMA, F4/80,
YAP, pSTAT3, GM130. More details are provided
in supplementary material, Supplementary materials
and methods.

RT-qPCR
Snap-frozen kidneys were homogenised using Magnalyser technology (Roche, Basel, Switzerland). Total
RNA was isolated using Tri-Reagent (Sigma-Aldrich).
cDNA synthesis was performed using the Transcriptor
First Strand cDNA Synthesis Kit (Roche), and qPCR
performed using ×2 FastStart SYBR-Green Master
(Roche) according to the manufacturer’s protocol.
Primer sequences are provided in supplementary material, Table S1. Levels of mRNA were normalised to
Hprt and fold-change was used for representation in the
graphs.

Statistical analysis
Data were analysed using ANOVA in GraphPad Prism
8.00 for Windows (GraphPad Software, San Diego, CA,
USA) and linear-mixed effects models in IBM SPSS
Statistics for Windows, version 23 (IBM Corp., Armonk,
NY, USA).

Results
Mice double KO for Pkd1 and Fjx1 survive longer
after toxic tubular damage compared with mice
single KO for Pkd1
Inactivation of the Pkd1 gene was achieved by oral
administration of tamoxifen in adult mice. This type of
mouse model is characterised by a relatively slow cyst
growth that allows having reasonable time windows for
the study of the different steps of disease progression.
We showed previously that upon nephrotoxic injury
cyst initiation is faster in mice with Pkd1 deletion compared with the non-injured group [8]. Using the same
injury model, we administered the nephrotoxic compound DCVC to Wt, Pkd1 KO, Fjx1 KO and double KO
mice (Figure 1A). We used PBS injection as a control
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Figure 1. BUN level after DCVC injection and during disease progression. (A) Graphical representation of the mouse experiment pipeline.
Adult mice (13–14 weeks old) were fed with 5 mg/day of Tamoxifen for 3 days (week −1). A week later they were injected i.p. with 15 mg/kg
of DCVC or PBS as a control (week 0). Mice were sacrificed 1, 2, 5 and 10 weeks after DCVC or PBS injection and at kidney failure, indicated
by a rise in BUN over 25 mmol/l. (B) BUN level in the first weeks after DCVC injection. All the genotypes were back to normal level after a
week post injury induction. (C) BUN level in Pkd1 KO mice and (D) in double KO mice with (black solid line) and without (grey dashed line)
injury. Each line represents a mouse. Kidney failure was accelerated by DCVC treatment in Pkd1 KO mice (median DCVC group: 14 weeks;
median PBS group: 19 weeks; Mann–Whitney test, P value < 0.05) but not in double KO mice (median DCVC group: 20 weeks; median PBS
group: 21 weeks), which reached kidney failure significantly later than Pkd1 KO + DCVC (two-way ANOVA with Tukey’s multiple comparisons
test, P value < 0.05). (E) Representative whole-mount kidneys at renal failure (Pkd1 KO and double KO) or 24 weeks after DCVC (Wt and
Fjx1 KO). Pkd1 KO and double KO kidneys showed enlarged cystic kidneys, compared to Wt and Fjx1 KO kidneys which did not show any
visible alteration.

(vehicle group). At 40 h after DCVC injections, renal
injury was confirmed by a substantial rise in the BUN
level in all mice, which returned to baseline after 1 week,
suggesting a full recovery of the kidney function with no
differences among the genotypes (Figure 1B).
Pkd1 KO mice injected with DCVC reached end-stage
renal disease (ESRD) around 14 weeks after injury. This
was significantly earlier than in the vehicle group, which
survived for about 19 weeks, in accordance with previously generated data (Figure 1C) [8]. Surprisingly,
we observed that the double KO mice did not show a
difference between DCVC and vehicle treatment with
a median survival of 20 and 21 weeks, respectively
(Figure 1D). When compared with Pkd1 KO mice, double KO mice survived significantly longer after injury,
indicating that the lack of Fjx1 improved survival of double KO mice upon renal damage.
Both Wt and Fjx1 KO mice subjected to renal injury
did not develop cysts still 24 weeks after DCVC, the time
point when mice were sacrificed (Figure 1E and data not
shown).

Knocking-out Fjx1 in Pkd1 mutant mice does not
affect cyst formation
Since renal injury accelerates cyst formation in Pkd1
KO mice [8,21–24], we wondered whether prolonged
survival observed in the double KO group treated with
DCVC could be due to delayed cyst initiation. We
measured the cystic index in kidneys from Pkd1 KO
and double KO mice at 10 weeks after DCVC injection when mice start to show a mild cystic phenotype.
We compared Pkd1 KO and double KO mice with and
without DCVC, and did not find any difference in the
cystic index, and two kidneys weight to body weight
(2KW/BW) ratios between the genotypes at this time
point (Figure 2A–C). Thus, the initiation of cyst formation is not different in the two models, suggesting a
role in cyst growth. This was also evident when ESRD
kidneys were compared. Indeed, Pkd1 KO mice injected
with DCVC, which reached ESRD faster, had a shorter
phase of cyst growth and displayed mainly small cysts
at kidney failure. Conversely, double KO mice, which
had a slower progression to ESRD and therefore a longer
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Figure 2. Cysts formation at 10 weeks after DCVC. (A) Representative PAS staining of Pkd1 KO and double KO mice kidneys at 10 weeks
after DCVC, showing comparable cyst formation in the two genotypes. Scale bars, 1 mm. (B) Evaluation of kidney size at the 10 week time
point in Pkd1 KO and double KO mice with and without injury using two kidney weight/body weight ratio. (C) Cystic index at the 10 week
time point in Pkd1 KO and double KO mice with and without injury. Each symbol shows data from one mouse. Mean ± SD. Two-way ANOVA
with Tukey’s multiple comparisons test.

phase of cyst growth, showed frequently larger cysts
(Figure 3A,B). Thus, our data suggest that Fjx1 is not
directly involved in cyst formation and that prolonged
survival of the double KO mice cannot be explained by
delayed cyst formation.

Chronic injury caused by cyst formation leads
to differences in injury markers expression, fibrosis
and inflammatory responses in double KO compared
with Pkd1 KO mice
Cyst formation is accompanied by inflammation
and fibrosis which ultimately lead to complete loss
of renal function. As changes in these processes might
affect survival, we analysed whether Fjx1 deletion
altered the expression of injury markers, fibrosis and
inflammation.
The expression of the well-established kidney injury
molecule Kim1 (Havcr1) [25] was analysed using
RT-qPCR. We observed increased Kim1 expression
already at 10 weeks after DCVC injection in Pkd1 KO
and in double KO mice, a time-point when dilation of
tubules and small cysts was evident. In contrast, Wt and
Fjx1 KO mice, which did not develop a renal phenotype
after DCVC injection, did not show increased Kim1
expression, reinforcing the idea of cyst-induced chronic
injury (Figure 4A). Interestingly, at kidney failure,
Kim1 expression was significantly higher in Pkd1 KO
mice compared to double KO (Figure 4B).
When we analysed fibrogenesis at 10 weeks after
DCVC and kidney failure, expression of alpha-1 type

I collagen (Col1a1) and Vimentin (Vim) was significantly reduced in the double KO compared to Pkd1
KO at 10 weeks after DCVC, both at the mRNA
(Figure 4C,D) and protein levels (Figure 5A,B); expression of Fibronectin (Fn1) showed a similar trend
(Figure 4C,D). Interestingly, in Pkd1 KO mice the
expression of these genes was significantly correlated
with kidney size, but this was not observed in the double
KO mice, suggesting that in these mice cyst progression
and fibrosis are two independent events (see supplementary material, Figure S1). Likewise, the expression
of transforming growth factor beta-1 (Tgfb1) was significantly less in double KO compared to Pkd1 KO
mice at 10 weeks and showed a similar trend at kidney
failure. Also, double KO mice at 10 weeks exhibited
a trend for lower alpha-smooth muscle actin (Acta2)
transcript levels and significantly less αSMA-positive
area (Figures 4E,F and 5C,D).
To characterise the inflammatory response, we looked
at the level of transcripts for the macrophage marker
Adgre1 (F4/80) and found this to be significantly less
abundant in double KO compared to Pkd1 KO mice at
kidney failure (Figure 4E,F). At 10 weeks after DCVC
Adgre1 showed a trend but at the protein level F4/80
expression was significantly reduced in double KO
mice (Figure 5E,F). We also assessed the expression of
Jak2 and Stat1, involved in the transduction of a series
of signals, such as growth factors and cytokines, in
response to injury [26]. We found significantly lower
expression in double KO compared to Pkd1 KO mice
(Figure 5G,H). On the other hand, Stat3 activation,

© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org

J Pathol 2019; 249: 114–125
www.thejournalofpathology.com

118

C Formica et al

Figure 3. Cysts size at kidney failure. (A) Representative PAS staining of kidneys of Pkd1 KO and double KO mice at kidney failure. Scale
bars, 1 mm. (B) Quantification of cysts size frequency in Pkd1 KO and double KO mice with and without injury. Data represent the mean of
4 mice ± SD. Three-way ANOVA (P value < 0.0001) with Tukey’s multiple comparisons test. *P value < 0.05.

known to be involved in cyst growth [27], was not
significantly different between the two genotypes,
supporting the idea that Fjx1 role is related to the
inflammatory/fibrotic response and not to cyst formation (see supplementary material, Figure S2). These
results indicate that the lack of Fjx1 leads to a reduced
inflammatory/fibrotic response which translates into a
longer survival after DCVC administration.

Investigation of pathways involved in renal fibrosis
We also studied the expression of key genes of several pathways known to be involved in renal fibrosis,
such as Notch [28,29], Hedgehog [30,31], Wnt [32,33],
hypoxia [34–38] and Egf [39–41]. However, we could
not find any differences between the double KO and
Pkd1 KO mice, except for target genes of Pdgfb- (see
supplementary material, Figure S3) and Wnt. Indeed,
Axin2, Cd44, Ccnd1 (Figure 6A,B) and to certain extent
Myc (see supplementary material, Figure S4), showed
significantly lower expression in double KO compared
with Pkd1 KO mice, both at 10 weeks after DCVC and
at kidney failure, suggesting a reduced activation of the
canonical Wnt signalling in the absence of Fjx1.

Mice double KO for Pkd1 and Fjx1 show less
sensitivity to DCVC-induced injury than mice single
KO for Pkd1
To further investigate the role of Fjx1 in injury, we
performed a pilot experiment in which mice treated
with DCVC were sacrificed after 24, 48 and 72 h, i.e.
during the nephrotoxin-induced acute injury phase. At
all time-points, we found a trend consistent with that

observed in the cyst-induced chronic injury, showing
that Kim1 expression was less in double KO mice than
in Pkd1 KO. At 1 week after DCVC Kim1 expression
was strongly reduced in both genotypes suggesting that
the DCVC-induced acute injury is largely repaired in
the first week (see supplementary material, Figure S5).
In line with the findings from the chronic injury experiments, the expression of genes involved in fibrogenesis,
such as Cola1a, Vim and Fn1, was lower in double KO
compared with Pkd1 KO mice (see supplementary material, Figure S5).
Together with the results observed during the
cyst-induced chronic injury, these data suggest that
the lack of Fjx1 leads to a reduced sensitivity to
DCVC-induced injury.

PCP is altered in Pkd1 mutant mice after injury but
is not significantly affected by the lack of Fjx1
Tissue injury causes inversion or loss of PCP in epithelial cells, and this recovers during the repair phase [42].
Fj has been described as an important PCP gene in
Drosophila as is Fjx1 in mammals, in particular in the
regulation of the brain architecture [13] and inner ear
polarity [14]. Therefore we decided to characterise renal
PCP at 1 week after injury in Pkd1 KO and double
KO mice.
The levels of expression of Fat4 and its ligand Dchs1
[43] were unchanged by Fjx1 KO (Figure 6C) suggesting that, at the expression level, the Ft/Ds PCP pathway was unaltered in kidneys of mutant mice. We also
used the position of the Golgi body to assess the degree
of polarity perturbation in tubular cells (Figure 6D).
Although Golgi position is not a direct read-out of PCP
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Figure 4. Expression of genes involved in injury-repair in Pkd1 KO and double KO mice. (A) Gene expression of Kim1 (Havcr1) at 10 weeks
after DCVC injection. Both Pkd1 KO and double KO have a significant increase of Kim1 expression compared to the PBS groups and the Wt
and Fjx1 KO with and without injury (significance not shown on graph), but not compared to each other. (B) Gene expression of Kim1 at
kidney failure after DCVC injection (significance to Wt and Fjx1 KO not shown on graph). (C) Col1a1, Vim and Fn1 mRNA levels at 10 weeks
after DCVC injection. (D) Col1a1, Vim and Fn1 mRNA levels at kidney failure. (E) Acta2, Tgfb1 and Adgre1 (F4/80) mRNA levels at 10 weeks
after DCVC injection and (F) at kidney failure. Each symbol shows data from one mouse. Mean ± SD. Two-way ANOVA with Tukey’s multiple
comparisons test. *P value < 0.05; **P value < 0.01; ***P value < 0.001.
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Figure 5. Fibrosis, fibroblast activation and macrophage infiltrate in Pkd1 KO and double KO mice. (A) Representative PSR staining of Pkd1
KO and double KO mouse kidney at 10 weeks after DCVC. Scale bars, 50 μm. (B) Quantification of PSR staining in the cortico-medullary
region. (C) Representative αSMA staining of Pkd1 KO and double KO mice at 10 weeks after DCVC. Scale bars, 50 μm. (D) Quantification of
αSMA staining in the cortico-medullary region. (E) Representative F4/80 staining of Pkd1 KO and double KO mice at 10 weeks after DCVC.
Scale bars, 50 μm. (F) Quantification of F4/80 staining in the cortico-medullary region. Each symbol is a mouse and data represent the
mean ± SD. Two-way ANOVA with Tukey’s multiple comparisons test. *P value < 0.05; **P value < 0.01. (G) Stat1 and Jak2 mRNA levels at
10 weeks after DCVC in Pkd1 KO and double KO mice. (H) Stat1 and Jak2 mRNA levels at kidney failure in Pkd1 KO and double KO mice
treated with DCVC. Each symbol shows data from one mouse. Mean ± SD. Unpaired t-test. *P value < 0.05; **P value < 0.01.

core proteins, it is found to be aberrant when PCP genes
are knocked-out [44], and is also associated with loss
of directed secretion, cell polarity and wound healing
capacity [45].
We confirmed that altered polarity was associated
with loss of Pkd1 and kidney injury already at the

pre-cystic stage, with a significantly more aberrant Golgi
position in Pkd1 KO and double KO mice compared
with Wt and Fjx1 KO. However, we could not identify
any difference between double KO and Pkd1 KO or
between Wt and Fjx1 KO (Figure 6E), indicating that
Fjx1 did not contribute to an altered PCP.
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Figure 6. Expression of Wnt pathway target genes and expression level of Fjx1 targets and Golgi position in tubular cells. (A) Axin2, Cd44
and Ccnd1 mRNA levels at 10 weeks after DCVC injection. (B) Axin2, Cd44 and Ccnd1 mRNA levels at kidney failure. (C) Fat4 and Dchs1
mRNA levels at 1 week after DCVC injection. Each symbol shows data from one mouse. Mean ± SD. Two-way ANOVA with Tukey’s multiple
comparisons test. *P value < 0.05; **P value < 0.01; ***P value < 0.001. (D) Representative GM130 (green) staining on kidney tissue. Nuclei
are stained in blue. In the normal situation, the Golgi body is positioned in a peri-centrosomal position at the top of the nucleus towards
the lumen of the tubules, but after injury we often observed altered Golgi position. Scale bars, 10 μm. (E) Golgi position has been scored
from 1 (normal position) to 3 (very abnormal position) in the round shaped tubules in the cortico-medullary region. Results are represented
as the percentage of aberrant Golgi position (score ≥ 2.5) per tubules. Each symbol is the mean ± SD of about 90 tubules scored in a mouse.
Two-way ANOVA with Fisher’s LSD. **P value < 0.01.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org
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The effect of Fjx1 on injury response is not
mediated by the Hippo pathway
Fjx1 is thought to be an upstream regulator of the
Hippo pathway through the activity of Fat4 [46]. The
Hippo pathway is pivotal in the regulation of organ
growth, tissue renewal and regeneration [47] but is also
deregulated in ADPKD [17]. Therefore, we investigated
this pathway in Pkd1 KO and double KO mice after
DCVC treatment.
Immunostaining of kidney sections for Yap confirmed the pattern described previously in our lab, with
increased nuclear localisation of Yap in the cystic epithelium [17]. However, we could not detect any significant difference between double KO and Pkd1 KO. Also,
neither mRNA levels of Yap1 and its paralog Taz, nor
their transcriptional targets, Amotl2, Cyr61, Wtip, Ctgf ,
Ajuba (see supplementary material, Figure S6), showed
any significant difference among genotypes. This suggests that despite the clear nuclear localisation of Yap in
the cystic epithelium this pathway is not responsible for
the difference in survival between Pkd1 KO and double
KO mice.
Taken together, these data indicate that knocking-out
Fjx1 does not affect PCP and the Hippo pathway in the
kidneys. Therefore, the differences observed in response
to injury in double KO mice cannot be explained by the
effect of Fjx1 on one of its canonical targets but suggests
the existence of other, yet unknown, Fjx1 targets.

Discussion
In this study we showed that nephrotoxic injury can
accelerate disease progression in Pkd1 KO mice but that
this effect is abolished in the absence of Fjx1 expression, allowing the Pkd1/Fjx1 double KO mice to survive on average 5 weeks longer than the single Pkd1
KO mice. Interestingly, the initiation of cyst formation
and cyst growth were not different among the two models, as shown by 2KW/BW ratios and the cystic index.
At 10 weeks after DCVC and kidney failure, however,
we observed a reduction in injury marker expression
together with reduced fibrosis and macrophage infiltration in Pkd1 KO mice compared with double KO. Therefore, these data suggest that Fjx1 does not play a critical
role in cyst formation and expansion but seems to be
involved in the fibrotic and inflammatory response to
injury. As a result, the mice lacking both, Fjx1 and Pkd1,
have less fibrosis, which leads to a slower progression to
ESRD and longer survival.
Fj is – together with the Ft-Ds cassette – part of a
signalling complex that is involved in the regulation of
PCP in Drosophila [48–51]. Nevertheless, the absence
of Fjx1 did not alter PCP in the kidneys when compared
with Wt mice, or in double KO compared to Pkd1 KO
mice. Although we observed significant deregulation
of PCP in pre-cystic kidneys after injury in both single
Pkd1 mutant mice and double KO, the additional deletion of Fjx1 did not further change the PCP phenotype

C Formica et al

in the Pkd1 KO. These results are consistent with the
published work of Probst et al [13] showing that Fjx1
KO mice do not have aberrant PCP in the kidneys but
show only defects in neuronal branching. An effect
on renal PCP was only seen after knocking-out Fat4,
a target of Fjx1, suggesting a more indirect effect of
Fjx1 on PCP in mammals [14,19]. We showed in a
previous study that PCP is impaired in Pkd1 KO mice
but not in Wt mice after injury, and that Pkd1 KO mice
injected with DCVC also develop cysts earlier when
compared with the PBS group [8]. Whether pre-cystic
alterations of PCP are critical for cyst formation is still
controversial. Several studies are suggesting that PCP
and cilium-associated control of oriented cell division
(OCD) as well as convergent extension (CE) are necessary during renal tubular morphogenesis and also
during proliferation phases in adult kidneys. Alterations
of both OCD and CE are involved in PKD [23,52–54].
However, there are also studies showing that alterations
in OCD and CE occur only after cyst formation, or that
mutations of PCP-core proteins do not result in cyst
formation [55,56]. This means that simple alteration
of PCP is not sufficient to start cyst formation but disrupted PCP together with other events, such as injury,
presumably increases the likelihood of cyst initiation.
Another pathway altered in ADPKD is the Hippo
pathway, which is also regulated via the Fjx1 target Fat4. In particular, the pathway’s effectors Yap1
and Taz have been associated with cyst formation. We
showed in the past that Yap1 accumulates in the nuclei
of the cyst-lining epithelium [8,17], and other groups
showed how deregulations of Yap1 activity could induce
cyst formation in Zebrafish models [57,58]. Moreover,
knocking-out Taz in mice leads to glomerular and proximal tubular cyst formation [59–61]. Nevertheless, we
did not see an effect of Fjx1 on the Hippo pathway
when comparing Pkd1 KO and double KO mice. Yap1
and Taz levels, as well as the levels of several of their
target genes, were comparable in the two genotypes
throughout disease progression. Also, Fat4 levels were
unchanged by Fjx1 deletion (data not shown). Currently,
clear proof that the Fjx1-Fat4-Dchs cassette interaction
controls PCP and Hippo pathway in kidneys is still missing [14,19,62].
Once cysts start to form and expand, they compress
the surrounding tissue, compromise the normal tubular structure and also interfere with the extracellular
compartment. This is accompanied by the expression
of injury markers and activation of transcription factors like Stat3, Creb and ERK, known to be involved
in ADPKD pathogenesis, and with an increased likelihood of more cyst formation [22,27,63,64]. All these
cues are perceived by the organ like a constant injury
insult and accompanied by a fibrotic and inflammatory
response. Concomitantly, a severe cystic phenotype is
associated with renal function decline due to the accumulation of fibrosis and inflammatory infiltrates, which
interfere with normal organ function [65,66]. Nonetheless, it is unclear whether inflammation and fibrosis are
responsible for or just a consequence of cyst formation.
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In our study, we observed separation between cyst formation and fibrotic response when Fjx1 is inactivated.
Indeed double KO mice had significantly reduced fibrosis and leukocytes infiltrates compared with Pkd1 KO
mice even though cyst formation was comparable. We
could exclude the involvement of some fibrosis-related
pathways, such as Notch, Hedgehog, hypoxia and Egfr
signalling, while we found a significant reduction of
expression of Pdgfb, Tgfb1, Jak2 and Stat1, and Wnt
pathway target genes in double KO compared to Pkd1
KO mice. Considering the well described role of Tgfb
and Wnt pathways in renal fibrosis [32,33,67,68], it is
plausible to think that they might be responsible for the
reduced fibrosis observed in double KO mice. Indeed,
Tgfb can regulate the expression of Pdgfb [69], Fn1 and
type I collagen [70,71] all found downregulated in double KO mice. Similarly, Wnt targets Axin2 [72], Cd44
[73], Ccnd1 [74,75] and Myc [76] were lower in double
KO mice. Further studies are required to link Fjx1 with
the Tgfb and Wnt pathways mechanistically. An interesting connection between Fjx1 and Jak/Stat pathways
has been described in the literature, with Fj as the effector of the pleiotropic pathway Jak/Stat in Drosophila
[10]. Although it is tempting to speculate that this might
be the route through which Fjx1 modulates the injury
response, it is more likely that reduced Jak2/Stat1 levels in the double KO mice mirror a reduced inflammatory response. Overall, these data suggest that Fjx1
is involved in the fibrotic/inflammatory response after
injury. We also showed that a different response to injury
in the double KO mice could also play a role during
the acute injury phase between 24 and 72 h after DCVC
injection. This is not surprising, considering that Fjx1
is mainly expressed in the developing kidneys while
its expression is almost absent in adult kidneys [77].
Indeed, as for many other developmental genes, injury
causes an increase in expression of Fjx1 [8]. Yet, the
mechanism through which Fjx1 is influencing these processes is still unclear.
As the function of Fjx1 is still obscure, we cannot
exclude that, besides the canonical targets Ft and Ds,
additional direct targets of Fjx1 exist. This is because
Fjx1 is a Golgi secretory pathway kinase and therefore
likely involved in many biological processes, as already
shown for its closely related homolog Fam20C [78,79].
Additionally, Fjx1 protein undergoes partial proteolytic
cleavage at the N-terminus, with the secretion of the
resultant fragment that can function as signalling ligand, influencing surrounding cells. Fjx1 fusion protein
experiments have shown several Fjx1 binding sites
present in different organs, including kidneys [77].
Therefore, a better understanding of Fjx1 functions in
mammals might help to explain the effect we unveiled
on fibrogenesis.
In conclusion, we show that cyst progression and
fibrosis in Pkd1/Fjx1 double KO mice are partially
uncoupled and demonstrate a new, yet undefined, role of
Fjx1 in fibrosis, ultimately resulting in longer survival.
Unveiling the underlying molecular mechanism might
open the path for future therapies that can specifically
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target injury-induced fibrosis, and could not only help
to slow down ADPKD, but also the progression of other
chronic kidney diseases.
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